<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263857</url>
  </required_header>
  <id_info>
    <org_study_id>REBB3M</org_study_id>
    <nct_id>NCT04263857</nct_id>
  </id_info>
  <brief_title>Register of Blood Stem Cell Transplantation</brief_title>
  <acronym>REBB3M</acronym>
  <official_title>Register of Survey and Evaluation of Blood Stem Cell Transplantations of Clinic III of Internal Medicine III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Register of patients with blood stem cell transplantations (autologous, allogen).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Documenting the success rate in terms of complication rate, disease response, survival rate,
      engraftment, and details of transplantation settings, for example donor and conditioning
      data, remission status before transplantation.

      It's a register of patients who have one or more autologous and / or allogenic blood stem
      cell transplants due to an existing indication for performing myeloablative /
      non-myeloablative high-dose chemotherapy.

      The inclusion occurs at our center during preparation for blood stem cell transplantation.
      The written consent will be obtained separately in the context of the information on blood
      stem cell transplantation. Participation is voluntary and consent can be revoked at any time.
      This involves no additional effort for the patient and has no influence on his treatment. It
      may be necessary in the course of contacting the patient at home, as long as the data is
      incomplete. This is also explicitly explained. A copy of the declaration of consent is given
      to the patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">November 2037</completion_date>
  <primary_completion_date type="Anticipated">November 2037</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Register of stem cell transplantation</measure>
    <time_frame>approximately over 20 years</time_frame>
    <description>Recording of all stem cell transplantations over many years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Register of toxicities</measure>
    <time_frame>approximately over 20 years</time_frame>
    <description>Recording of toxicities occured during and after SCT according to GvHD Score Standards and blood and bone marrow samples, and Imaging (CT Scans)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Register of complications</measure>
    <time_frame>approximately over 20 years</time_frame>
    <description>Recording of complications occurred during and after SCT in Terms of infectious complications and occurance of GvHD (according to GvHD Score and Imaging and clinical assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Register of morbidities</measure>
    <time_frame>approximately over 20 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Register of survivals</measure>
    <time_frame>approximately over 20 years</time_frame>
    <description>Recording of survival Status, Assessment of Remission Status by bone marrow and blood diagnostics, clinical follow up</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Hematologic Malignancies</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all adults, Age &gt;= 18 years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed IC

          -  patients eligible for stem cell transplantation

        Exclusion Criteria:

          -  unable to consent to study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mareike Verbeek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar der TU Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mareike Verbeek, MD</last_name>
    <phone>+49 89 4140</phone>
    <phone_ext>5336</phone_ext>
    <email>mareike.verbeek@tum.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mareike Verbeek, MD</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>5336</phone_ext>
      <email>mareike.verbeek@tum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous &amp; allogenic blood stem cell transplantations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

